Supplements

Early ultrasound-guided thoracic paravertebral block reduces postherpetic neuralgia incidence in acute herpes zoster patients

In a randomized clinical trial of 100 patients with acute thoracic herpes zoster, adding ultrasound-guided thoracic paravertebral block (TPVB) with bupivacaine and methylprednisolone to standard therapy significantly reduced the incidence of postherpetic neuralgia at 90 days (16% vs. 34%, P=0.037). The TPVB group also showed improved pain scores, quality of life, sleep quality, and functional disability at 3 and 6 months.

Last updated: Jul 14, 2026•1 RCTs•📖 Read as article →

Evidence Score

Evidence Score44/100
Human RCT★★☆☆☆
Meta-analysis☆☆☆☆☆
Mechanism★★★★★
Safety★★★★☆
Confidencelow

Study Evidence

Study 1. Early ultrasound-guided thoracic paravertebral block reduces postherpetic neuralgia and improves functional outcomes in acute herpes zoster: a randomized clinical trial.

observational

Mahmoud Abdallah AO, Abdelrady MM, Omar Mahmoud H, Mohamed Hasan Eisa MA · Revista espanola de anestesiologia y reanimacion (2026)

Participants: N/A
Duration: 6 months
Intervention: Ultrasound-guided thoracic paravertebral block with 0.25% bupivacaine and 40 mg methylprednisolone, performed at 48-hour intervals for three sessions, plus standard medical therapy
Outcome: Incidence of postherpetic neuralgia at 90 days (primary), pain intensity (NRS), quality of life (SF-36), sleep quality (PSQI), functional disability (PDI), neuropathic pain (DN4), rescue analgesic consumption, patient satisfaction, adverse events
Effect Size: Absolute risk reduction of 18% for PHN at 90 days (16% vs. 34%)
Population: 100 patients with acute thoracic herpes zoster (rash duration ≤14 days, NRS ≥4)

Result:

PubMed: 42431311DOI: 10.1016/j.redare.2026.502176

Mechanism Graph

Local anesthetic blocks nociceptive input from affected dorsal root ganglia
↓
Corticosteroid reduces inflammation and neural damage
↓
Early intervention prevents central sensitization and chronic pain pathways
↓
Result: Reduced incidence of postherpetic neuralgia and improved functional outcomes

Limitations

  • ⚠Single-center study with relatively small sample size (n=100)
  • ⚠No sham or placebo block in the control group, limiting blinding
  • ⚠Follow-up limited to 6 months; longer-term durability of effect not assessed

Frequently Asked Questions

How does early TPVB reduce the risk of postherpetic neuralgia?▼

By blocking nociceptive input and reducing inflammation early in the acute phase, TPVB may prevent central sensitization and chronic pain development.

What are the key benefits of TPVB beyond pain relief?▼

The study found significant improvements in sleep quality (PSQI), functional disability (PDI), and overall quality of life (SF-36) at 3 and 6 months.

Is TPVB safe for acute herpes zoster patients?▼

No serious block-related complications were reported, suggesting it is a safe adjunctive therapy when performed under ultrasound guidance.

How long after rash onset should TPVB be performed?▼

The study included patients with rash duration ≤14 days, and blocks were performed at 48-hour intervals for three sessions, indicating early intervention is key.

Products

Affiliate links coming soon. We only recommend products that match the doses and forms used in the cited research.

References

  1. 1.Mahmoud Abdallah AO, Abdelrady MM, Omar Mahmoud H, Mohamed Hasan Eisa MA. "Early ultrasound-guided thoracic paravertebral block reduces postherpetic neuralgia and improves functional outcomes in acute herpes zoster: a randomized clinical trial.." Revista espanola de anestesiologia y reanimacion, 2026. PMID: 42431311 DOI: 10.1016/j.redare.2026.502176
Disclaimer: This content is for educational purposes only and is not medical advice. Evidence scores reflect the quality and quantity of available research, not clinical recommendations. Always consult a healthcare professional before starting any supplement or intervention.